

REMARKS

Claims 1, 5, 29-35, 38, and 39-46 will be pending in the present application upon entry of the above claim amendment. Claims 1, 5, 29-35, 38, and 39 were previously pending in the application and claims 40-46 are new. Claims 1, 5, 29-35, 38, and 39 were indicated to be allowable in the Notice of Allowance dated November 4, 2003. Claims 32, 38, and 39 as presented herein include the amendments indicated in the Examiner's Amendment that accompanied the Notice of Allowability.

All of the new claims depend from allowable claims. Applicants note that claim 41 corresponds to previously presented claim 7 and claim 43 corresponds to previously presented claim 17. New claims 45 and 46 correspond to previously presented claims 18 and 19.

Support for the new claims can be found throughout the application, for example at page 5, line 22- page 6, line 2; page 14, lines 17-27; page 7, line 27-page 8, line 4; and page 12, line 6-page 13, line 9. No new matter is added by the amendment.

In the Office Action dated August 13, 2002, the examiner stated "claims directed to a process of making or using the patentable product, previously withdrawn from consideration as a result of a restriction requirement, will be rejoined..." (Office Action page 3, item 5).

Applicants have filed the present Request for Continued Examination in order to pursue claims that are related to making or using a patentable product. Accordingly, in addition to reiteration of the allowance of claims 1, 5, 29-35, 38, and 39, applicants respectfully request allowance of new claims 40-46, all of which depend from the allowable claims.

Interview Summary

In telephone interviews with the Examiner on October 27, 2003, and October 30, 2003, Applicants' undersigned representative agreed to the following Examiner's amendments:

1. Cancel claims 2, 7, 11, 13, 14, 17, 20-28, and 36-37.
2. In claim 39, line 11, delete "Peptide #1-26 (SEQ ID NO:28),".
3. In claim 32, line 1, delete "treatment of a patient with".
4. In claim 32, line 2, immediately after "cedar pollinosis" add "--in a patient--".

Applicant : Kohsuke Kino et al.
Serial No. : 09/202,464
Filed : December 14, 1998
Page : 8 of 8

Attorney's Docket No.: 14883-024001 / M1-805PCT-
US

5. In claim 38, line 1, delete "claim 1" and insert in its place --claim 39--.

CONCLUSION

Enclosed is a check in the amount \$770 for the Request for Continued Examination fee.
Please apply any other charges or credits to deposit account 06-1050, referencing attorney docket
number 14883-024001.

Respectfully submitted,

Date: February 3, 2004



Lisa N. Geller, Ph.D., J.D.
Reg. No. 51,726

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
20797424.doc